Analysts/Institutional Investor Meet/Con. Call Updates

AI summary - Granules returned to growth in FY26, starting a new growth cycle - Four growth engines: controlled substances, complex generics, oncologies, peptide CDMO - First-to-file strategy progressing with two sole first-to-file ANDAs filed, pipeline for FY30-34 - Controlled substances business is third largest in US by value, with growing DEA quota - Peptide CDMO targets $50 million revenue run rate by FY29 and $100 million by FY31 - FY27 R&D investment at 6% of revenue, supporting differentiated products - Planned capex of Rs 2,000 Cr over 3-4 years for growth areas and digitalization - Gross margin improved 15 percentage points over 4 years; EBITDA margin up 3 points - Oncology pipeline includes 2 filed products and 6 more to file soon - DEA compliance strong with near flawless audits and quota increases annually